Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia
- PMID: 30370957
- DOI: 10.1002/ajh.25332
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia
Similar articles
-
Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.Leuk Lymphoma. 2012 Oct;53(10):2085-8. doi: 10.3109/10428194.2011.603450. Epub 2011 Sep 6. Leuk Lymphoma. 2012. PMID: 21740302 No abstract available.
-
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
-
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.Haematologica. 2016 Jul;101(7):839-45. doi: 10.3324/haematol.2015.141622. Epub 2016 Apr 1. Haematologica. 2016. PMID: 27036160 Free PMC article. Clinical Trial.
-
[Combination chemotherapy for acute myeloid leukemia].Nihon Rinsho. 2009 Oct;67(10):1921-5. Nihon Rinsho. 2009. PMID: 19860191 Review. Japanese.
-
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.Am J Hematol. 2017 Sep;92(9):E549-E552. doi: 10.1002/ajh.24804. Epub 2017 Jul 19. Am J Hematol. 2017. PMID: 28568483 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical